Ensysce Biosciences (ENSC) Other Non Operating Income (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Other Non Operating Income of $17338.0 for Q3 2025, up 18.08% year-over-year from $14683.0 in Q3 2024, and down 17.48% quarter-over-quarter from $21011.0 in Q2 2025.
Ensysce Biosciences (ENSC) Other Non Operating Income (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Other Non Operating Income for 8 consecutive years, with $17338.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Non Operating Income rose 18.08% year-over-year to $17338.0; the TTM figure through Sep 2025 stood at $83918.0 (up 511.89% YoY), while the FY2024 annual figure was $17277.0, up 12.04% from the prior year.
- Other Non Operating Income eased to $17338.0 in Q3 2025 per ENSC's latest filing, from $21011.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $712899.0 in Q2 2021 and bottomed at -$39585.0 in Q1 2021.
- Historically, Other Non Operating Income has averaged $51237.4 across 5 years, with a median of $11030.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 472.9% in 2024 and fell as far as 736.45% in 2024.
- Ensysce Biosciences' Other Non Operating Income stood at $65287.0 in 2021, then grew by 2.21% to $66729.0 in 2022, then slumped by 111.93% to -$7962.0 in 2023, then jumped by 472.9% to $29690.0 in 2024, then tumbled by 41.6% to $17338.0 in 2025.
- Business Quant data shows ENSC's Other Non Operating Income at $17338.0 in Q3 2025, $21011.0 in Q2 2025, and $15879.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 17,338.00 |
| Jun 30, 2025 | 21,011.00 |
| Mar 31, 2025 | 15,879.00 |
| Dec 31, 2024 | 29,690.00 |
| Sep 30, 2024 | 14,683.00 |
| Jun 30, 2024 | 7,394.00 |
| Mar 31, 2024 | -34,489.00 |
| Dec 31, 2023 | -7,962.00 |
| Sep 30, 2023 | 6,934.00 |
| Jun 30, 2023 | 11,030.00 |
| Mar 31, 2023 | 5,419.00 |
| Dec 31, 2022 | 66,729.00 |
| Sep 30, 2022 | 8,679.00 |
| Jun 30, 2022 | 2,850.00 |
| Mar 31, 2022 | 7,966.00 |
| Dec 31, 2021 | 65,287.00 |
| Sep 30, 2021 | 61,758.00 |
| Jun 30, 2021 | 712,899.00 |
| Mar 31, 2021 | -39,585.00 |
| Mar 31, 2020 | 2.78 Mn |